Cell-Based Assays Products & Reviews

Cytokeratin 5 & 6 (D5 & 16B4) Mouse Monoclonal Antibody

CD56 (MRQ-42) Rabbit Monoclonal Antibody

DAB Substrate Kit is intended for use in immunohistochemistry (IHC) staining protocols. This reagent is designed to detect target antigens in formalin-fixed, paraffin-embedded tissue sections when used in conjunction with primary antibodies and appropriate secondary antibody conjugates in the IHC staining process. When in the presence of HRP polymer, DAB produces a brown precipitate that can be readily visualized using light m…

GATA3 (L50-823) Mouse Monoclonal Antibody

Cytokeratin Cocktail (AE1 & AE3) Mouse Monoclonal Antibody

Diamond: Antibody Diluent

CD20 (L26) Mouse Monoclonal Antibody

CD138/syndecan-1 (B-A38) Mouse Monoclonal Antibody

SOX-11 (MRQ-58) Mouse Monoclonal Antibody

c-Myc (EP121) Rabbit Monoclonal Primary Antibody

CD34 (QBEnd/10) Mouse Monoclonal Antibody

CMV (8B1.2, 1G5.2 & 2D4.2) Mouse Monoclonal Antibody

CDX-2 (EPR2764Y) Rabbit Monoclonal Antibody

IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody

ATRX Rabbit Polyclonal Antibody

High plex proteomics instrument for spatial biology

Fast track precise spatial multiplexing

We offer extensive Toxicity & Safety Evaluation Services to identify potential risks in drug candidates early. Our comprehensive capabilities cover General, Local, Developmental, and Organ-Specific Toxicity (including liver, cardio, and neuro) across numerous animal species, administered via various routes, to characterize drug safety.

We offer extensive Antibody Functional Characterization Services, focusing on both Fab-based target binding and Fc-mediated effector functions. Our assays analyze mechanisms like Neutralization, ADCC, CDC, and ADCP, leveraging advanced platforms to select promising therapeutic candidates.

Creative Biolabs delivers an end-to-end CAR-T development pathway—from target/scFv discovery, CAR design and vectoring, and cell engineering to in-vitro/in-vivo efficacy, IND authoring, and manufacturing support. Modular and GMP-aligned, the platform spans autologous and allogeneic routes (incl. TRAC/Cas9 and mRNA) to de-risk translation for hematologic and solid tumor programs.

End‑to‑end TCR‑like antibody services targeting peptide–MHC complexes—covering immunogen design, pMHC screening, affinity maturation, developability optimization, and functional validation—with output as IgG, bispecifics, or CAR constructs to access intracellular‑derived antigens.

End‑to‑end solid‑tumor CAR‑T development—from antigen/scFv discovery and CAR optimization to cell engineering, in‑vitro/in‑vivo efficacy, and IND support. Incorporates dual/logic‑gated and armored CARs, plus trafficking and persistence enhancements to overcome the tumor microenvironment and improve safety and translation.

End‑to‑end allogeneic cell therapy development—covering donor strategy, multiplex genome editing for safety/immune evasion, scalable manufacturing and comparability, and IND/CMC support—across CAR‑T/CAR‑NK and other donor‑derived modalities to enable off‑the‑shelf access.

Configurable TIL therapy development spanning tumor processing, TIL isolation/rapid expansion, functional and phenotypic qualification, and release criteria—paired with manufacturing‑aligned process development and IND documentation to de‑risk scale‑up for solid‑tumor programs.

A comprehensive collection of active, recombinant protein kinases, crucial for screening and profiling small molecule inhibitors and studying cellular signaling pathways in disease.